ArticleCureus2025
Dermatologists' Experience in Managing Body Dysmorphic Disorder in Saudi Arabia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreoccupation with a perceived minor or non-existent flaw in physical appearance that negatively impacts a patient's quality of life is the cardinal feature of body dysmorphic disorder (BDD).
objectiveThis study aims too explore how commonly dermatologists in Saudi Arabia (SA) encounter BDD patients and their preferred management approach.
methodsWe conducted a cross-sectional study using a previously validated questionnaire that included information about participants' demographics, the frequency of exposure to BDD patients, and their management approach. We used a purposeful sampling technique, distributing the survey via Google Forms to 127 dermatologists living in SA, regardless of their age, gender, position, clinical setting, or work experience, over a period of one month.
resultsA total of 118 (93%) participants had encountered at least one BDD patient at some point throughout their working life. Two-thirds of participants are currently treating BDD patients. Seventy-eight participants (62%) consider patient reassurance and condition explanation as their primary approach to managing BDD patients, despite knowing that antidepressants are considered the first-line treatment.
conclusionMost dermatologists in SA are aware of BDD and encounter it in their daily practice. While they recognize that antidepressants are the first-line treatment and that early involvement of a psychiatrist is paramount, most prefer to simply explain the nature of the condition to the patient and provide reassurance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.